» Articles » PMID: 17908039

Practical Issues in Stem Cell Therapy for Alzheimer's Disease

Overview
Specialty Neurology
Date 2007 Oct 3
PMID 17908039
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

We have demonstrated that aged animals show significant improvements in cognitive function and neurogenesis after brain transplantation of human neural stem cells or of human adult mesenchymal stem cells that have been dedifferentiated by transfection of the embryonic stem cell gene. We have also demonstrated that peripheral administration of a pyrimidine derivative increased cognition, endogenous brain stem cell proliferation and neurogenesis. These results indicate a bright future for stem cell therapies in Alzheimer's disease (AD). Before this is realized, however, we need to consider the affect of AD pathology on stem cell biology to establish an effective stem cell therapy for this disease. Although amyloid-beta (Abeta) deposition is a hallmark of AD, an absence of a phenotype in the beta-amyloid precursor protein (APP) knockout mouse, might lead one to underestimate the potential physiological functions of APP and suggest that it is unessential or can be compensated for. We have found, however, that APP is needed for differentiation of neural stem cells (NSCs) in vitro, and that NSCs transplanted into a APP-knockout mouse did not migrate or differentiate -- indicating that APP plays an important role in differentiation or migration process of NSCs in the brain. Then again, treatment with high a concentration of APP or its over-expression increased glial differentiation of NSCs. Human NSCs transplanted into APP-transgenic mouse brain exhibited less neurogenesis and active gliosis around the plaque like formations. Treatment of such animals with the compound, (+)-phenserine, that is known to reduce APP protein levels, increased neurogenesis and suppressed gliosis. These results suggest APP levels can regulate NSC biology in the adult brain, that altered APP metabolism in Down syndrome or AD may have implications for the pathophysiology of these diseases, and that a combination of stem cell therapy and regulation of APP levels could provide a treatment strategy for these disorders.

Citing Articles

Neural Differentiation of Induced Pluripotent Stem Cells for a Xenogeneic Material-Free 3D Neurological Disease Model Neurulation from Pluripotent Cells Using a Human Hydrogel.

Valerio L, Carrick F, Bedoya L, Sreerama S, Sugaya K Curr Issues Mol Biol. 2023; 45(6):4574-4588.

PMID: 37367039 PMC: 10297326. DOI: 10.3390/cimb45060290.


Pharmacological Inhibition of the Asparaginyl Endopeptidase (AEP) in an Alzheimer's Disease Model Improves the Survival and Efficacy of Transplanted Neural Stem Cells.

Cheng Q, Ma X, Liu J, Feng X, Liu Y, Wang Y Int J Mol Sci. 2023; 24(9).

PMID: 37175445 PMC: 10178525. DOI: 10.3390/ijms24097739.


Drug repositioning and repurposing for Alzheimer disease.

Ballard C, Aarsland D, Cummings J, OBrien J, Mills R, Molinuevo J Nat Rev Neurol. 2020; 16(12):661-673.

PMID: 32939050 PMC: 8291993. DOI: 10.1038/s41582-020-0397-4.


Sequential combined Treatment of Pifithrin-α and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke.

Turcato F, Kim P, Barnett A, Jin Y, Scerba M, Casey A Cell Transplant. 2018; 27(4):607-621.

PMID: 29871513 PMC: 6041885. DOI: 10.1177/0963689718766328.


Adult human neural stem cell therapeutics: Current developmental status and prospect.

Nam H, Lee K, Nam D, Joo K World J Stem Cells. 2015; 7(1):126-36.

PMID: 25621112 PMC: 4300923. DOI: 10.4252/wjsc.v7.i1.126.